Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
36.50
+1.67 (4.79%)
At close: Aug 13, 2025, 4:00 PM
36.90
+0.40 (1.10%)
After-hours: Aug 13, 2025, 6:58 PM EDT
Harrow Revenue
Harrow had revenue of $63.74M in the quarter ending June 30, 2025, with 30.25% growth. This brings the company's revenue in the last twelve months to $227.66M, up 47.69% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$227.66M
Revenue Growth
+47.69%
P/S Ratio
5.51
Revenue / Employee
$595,971
Employees
382
Market Cap
1.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HROW News
- 1 hour ago - Harrow: Exciting Times In Store - Seeking Alpha
- 1 day ago - Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Harrow Announces Second-Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference - GlobeNewsWire
- 15 days ago - Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 - GlobeNewsWire
- 27 days ago - Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
- 27 days ago - Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States - Business Wire
- 4 weeks ago - HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire